Adverse effects of vancomycin in children
a review of 22 cases
Palavras-chave:
Vancomycin, Adverse effects, Children, AntibioticsResumo
Vancomicina é frequentemente recomendada para o tratamento de infecções causadas por Staphyloccus aureus multi-resistente. Foram observadas vinte e duas crianças recebendo tratamento com vancomicina. Foram registrados nove efeitos adversos em seis crianças: eosinofilia em cinco casos, exantema em dois casos e aumento da creatinina plasmática em dois casos. Todas as reações adversas regrediram com a retirada da droga.
Downloads
Referências
Geraci JE, Heilman FR, Nichols DR, Wellman WE, Ross GT. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proceedings of the Staff Meetings of the Mayo Clinic 1956;31:564-82.
Anderson JS, Matsuhashi M, Haskin MA, Strominger JL. Lipid-phosphoacetylmuramyl-pentapeptide and lipidphosphodisaccharide-pentapeptide: Presumed membrane transport intermediates in cell wall synthesis. Proc NAS 1965;53:881-9.
Wang WC, Wong WY, Rogers ZR, Wilimas JA, Buchanan GR, Powars DR. Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. J Pediatr Hematol Oncol 1996;18:140-4.
McGowan JE Jr, Metchock BG. Penicillin-resistant pneumococci: An emerging threat to successful therapy. J Hosp Infect 1995;30 Suppl:472-82.
Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995;20:826-35
Banner W Jr. Why read a pharmacokinetic article? AJDC 1986;140:104-6
Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet 1986;11:257-82.
Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14:667-73.
Logsdon BA, Lee KR, Barret FF. Correct dosing of vancomycin in infants and children. Pediatrics 1995;96:1177.
Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16:235-41.
Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: A prospective study. J Antimicrob Chemother 1985;15:773-80.
Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Internal Med 1961;55:235-49.
Odio C, Mohs, E, Sklar FH, Nelson JD, McCracken GH Jr. Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. AJDC 1984;138;17-9.
Nahata MC, King DR, Powell DA, Marx SM, Ginn-Pease ME. Management of catheter-related infections in pediatric patients. JPEN J Parenter Enteral Nutr 1988;12:58-9.
Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DR. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994;33:811-21.
Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis: VII vancomycin for acute micrococcal endocarditis. Proceedings of the Staff Meetings of the Mayo Clinic Nutr 1958;33:172-81.
Geraci JE, Hermans PE. Vancomycin. Mayo Clin Proc 1983;58:88-91.
Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26.
Shinohara YT, Colbert J. Vancomycin-induced neutropenia during treatment of endocárditis in a pediatric patient. Ann Pharmacother 1994;28:723-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
